Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Overview

Journal Comput Math Methods Med

Publisher Hindawi

Specialty Medical Informatics

Date 2022 Aug 22

PMID 35991143

Authors

Meng Cai

Jie Zhu

Guangxin Zhou

Affiliations

Soon will be listed here.

Abstract

Methods: The medical data of 47 patients with refractory bone and soft tissue sarcoma, who received anlotinib from January 2019 to December 2020, were retrospectively collected. The overall response rate (ORR) and disease control rate (DCR) were evaluated according to the solid tumor response evaluation version 1.1 standard. The progression-free survival (PFS), overall survival (OS), and adverse reactions were recorded.

Results: A total of 44 patients, including 13 with osteosarcoma and 31 with soft tissue sarcoma, were enrolled in this study. Among patients with osteosarcoma, no patients achieved complete response (CR) or partial response (PR), while seven patients (54%) had stable disease (SD). Besides, the median PFS (m-PFS) was 4.4 months, and the median OS (m-OS) was 15.7 months. Among patients with soft tissue sarcoma, the ORR and DCR were 19% and 71%, respectively. The median m-PFS was 5.4 months, and m-OS was 17.9 months. Anlotinib plus chemotherapy had a higher ORR compared with anlotinib monotherapy (6% vs. 38%, = 0.047). The most common grade 3/4 adverse reactions were pneumothorax (5%) and pleural effusion (5%), and no treatment-related deaths occurred.

Conclusions: Anlotinib alone showed encouraging efficacy and favorable tolerability in refractory bone and soft tissue sarcoma. Anlotinib plus chemotherapy did not show a significant clinical benefit compared with anlotinib alone. Anlotinib showed better tumor control when used as first-line drug treatment in refractory bone and soft tissue sarcoma.

Citing Articles

Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review.

Houmsse M, Muskara A, Pasca D, Roy A, Sughra S, Ghazi S Cancers (Basel). 2025; 17(5).

PMID: 40075674 PMC: 11899116. DOI: 10.3390/cancers17050827.

Denosumab combined with chemotherapy followed by anlotinib in the treatment of multiple metastases of malignant peripheral nerve sheath tumor: a case report and literature review.

Chen Q, Cui H, Zheng K, Xu M, Yu X Front Oncol. 2024; 14:1399021.

PMID: 39119091 PMC: 11306154. DOI: 10.3389/fonc.2024.1399021.

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.

Assi A, Farhat M, Hachem M, Zalaquett Z, Aoun M, Daher M J Bone Oncol. 2023; 43:100511.

PMID: 38058514 PMC: 10696463. DOI: 10.1016/j.jbo.2023.100511.

Malignant transformation of an aneurysmal bone cyst of the femoral neck: A case report.

Song X, Qiao Y, Zhang H, Sha L, Lou J, Yu X Exp Ther Med. 2023; 26(2):362.

PMID: 37408864 PMC: 10318599. DOI: 10.3892/etm.2023.12061.

Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology.

Yan Q, Yang J, Yao Y, Jia Z, Wang Y, Cheng M Comput Math Methods Med. 2022; 2022:7994425.

PMID: 36466554 PMC: 9713469. DOI: 10.1155/2022/7994425.

References

Wang G, Cao L, Jiang Y, Zhang T, Wang H, Wang Z . Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo. Front Pharmacol. 2022; 12:798837. PMC: 8801797. DOI: 10.3389/fphar.2021.798837. View

Maki R, DAdamo D, Keohan M, Saulle M, Schuetze S, Undevia S . Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27(19):3133-40. PMC: 2716936. DOI: 10.1200/JCO.2008.20.4495. View

Wang H, Chu J, Zhang P, Wang J, Yan Z, Yao S . Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma. Onco Targets Ther. 2020; 13:1561-1568. PMC: 7038775. DOI: 10.2147/OTT.S235349. View

Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E . Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2018; 20(1):120-133. DOI: 10.1016/S1470-2045(18)30742-3. View

Hirbe A, Eulo V, Moon C, Luo J, Myles S, Seetharam M . A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020; 137:1-9. DOI: 10.1016/j.ejca.2020.06.016. View

Liu Z, Gao S, Zhu L, Wang J, Zhang P, Li P . Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study. Cancer Med. 2021; 10(21):7593-7600. PMC: 8559478. DOI: 10.1002/cam4.4286. View

Huang M, Liu Y, Yu M, Li Y, Zhang Y, Zhu J . A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer. Invest New Drugs. 2021; 40(2):308-313. PMC: 8993710. DOI: 10.1007/s10637-021-01179-2. View

Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G . Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clin Cancer Res. 2018; 24(21):5233-5238. DOI: 10.1158/1078-0432.CCR-17-3766. View

Harrer D, Buschauer S, Sterz U, Menhart K, Wendl C, Heudobler D . Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas. Front Oncol. 2021; 11:755439. PMC: 8712329. DOI: 10.3389/fonc.2021.755439. View

10.

Grignani G, Palmerini E, Dileo P, Asaftei S, DAmbrosio L, Pignochino Y . A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2011; 23(2):508-16. DOI: 10.1093/annonc/mdr151. View

11.

Brewster R, Purington N, Henry S, Wood D, Ganjoo K, Bui N . Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma. JAMA Netw Open. 2021; 4(3):e210845. PMC: 7936255. DOI: 10.1001/jamanetworkopen.2021.0845. View

12.

Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H . Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019; 145(4):979-993. DOI: 10.1002/ijc.32180. View

13.

Wang Q, Peng H, Qi X, Wu M, Zhao X . Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020; 5(1):137. PMC: 7391668. DOI: 10.1038/s41392-020-0199-6. View

14.

Tian Z, Wang X, Liu Z, Wang J, Yao W, Zhao Y . Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions. Cancer Manag Res. 2019; 11:5293-5300. PMC: 6559225. DOI: 10.2147/CMAR.S207150. View

15.

Hall F, Villalobos V, Wilky B . Future directions in soft tissue sarcoma treatment. Curr Probl Cancer. 2019; 43(4):300-307. DOI: 10.1016/j.currproblcancer.2019.06.004. View

16.

Miwa S, Nishida H, Tanzawa Y, Takeuchi A, Hayashi K, Yamamoto N . Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017; 123(9):1576-1584. DOI: 10.1002/cncr.30606. View

17.

Comandone A, Petrelli F, Boglione A, Barni S . Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. Oncologist. 2017; 22(12):1518-1527. PMC: 5728024. DOI: 10.1634/theoncologist.2016-0474. View

18.

Zhou C, Wu Y, Chen G, Liu X, Zhu Y, Lu S . BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(19):2197-204. DOI: 10.1200/JCO.2014.59.4424. View

19.

Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E . Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(3):446-455. PMC: 8763616. DOI: 10.1016/S1470-2045(19)30825-3. View

20.

Wang Y, Delisle M, Smith D, Srikanthan A . Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis. Syst Rev. 2020; 9(1):189. PMC: 7441630. DOI: 10.1186/s13643-020-01445-z. View